FluoGuide has been awarded a grant together with Rigshospitalet (DK) to conduct a phase II trial with FG001 in patients with less aggressive brain cancers

Copenhagen, Denmark, 18 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce a grant of total 945 KDKK to conduct a phase II trial with FG001 in patients with less aggressive brain cancers.

The release as fetched from its publisher. fluoguide.com ↗